192 related articles for article (PubMed ID: 30570400)
1. From mother to baby: antenatal exposure to monoclonal antibody biologics.
Pham-Huy A; Sadarangani M; Huang V; Ostensen M; Castillo E; Troster SM; Vaudry W; Nguyen GC; Top KA
Expert Rev Clin Immunol; 2019 Mar; 15(3):221-229. PubMed ID: 30570400
[TBL] [Abstract][Full Text] [Related]
2. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study.
Tsao NW; Lynd LD; Sayre EC; Sadatsafavi M; Hanley G; De Vera MA
BMJ Open; 2019 Feb; 9(2):e023714. PubMed ID: 30787081
[TBL] [Abstract][Full Text] [Related]
3. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
Wieringa JW; Driessen GJ; Van Der Woude CJ
Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
[TBL] [Abstract][Full Text] [Related]
4. Safety issues of biologics in pregnant patients with rheumatic diseases.
Ostensen M
Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
[TBL] [Abstract][Full Text] [Related]
5. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
6. The new biologics in pregnancy.
Pupco A
J Popul Ther Clin Pharmacol; 2014; 21(3):e548-54. PubMed ID: 25527794
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.
Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
9. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of children exposed antenatally to immunosuppressive drugs.
Motta M; Tincani A; Meroni PL; Cimaz R
Rheumatology (Oxford); 2008 Jun; 47 Suppl 3():iii32-4. PubMed ID: 18504283
[TBL] [Abstract][Full Text] [Related]
11. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.
Tsao NW; Sayre EC; Hanley G; Sadatsafavi M; Lynd LD; Marra CA; De Vera MA
Ann Rheum Dis; 2018 Jun; 77(6):869-874. PubMed ID: 29496718
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M
Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831
[TBL] [Abstract][Full Text] [Related]
14. The use of biologics and small molecules in pregnant patients with rheumatic diseases.
Gerosa M; Argolini LM; Artusi C; Chighizola CB
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):987-998. PubMed ID: 30227748
[TBL] [Abstract][Full Text] [Related]
15. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes after maternal exposure to rituximab.
Chakravarty EF; Murray ER; Kelman A; Farmer P
Blood; 2011 Feb; 117(5):1499-506. PubMed ID: 21098742
[TBL] [Abstract][Full Text] [Related]
17. Treatment with biologics of pregnant patients with rheumatic diseases.
Ostensen M; Förger F
Curr Opin Rheumatol; 2011 May; 23(3):293-8. PubMed ID: 21346578
[TBL] [Abstract][Full Text] [Related]
18. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
19. Safety of infliximab use during pregnancy.
Djokanovic N; Klieger-Grossmann C; Pupco A; Koren G
Reprod Toxicol; 2011 Jul; 32(1):93-7. PubMed ID: 21621603
[TBL] [Abstract][Full Text] [Related]
20. [Anti-tumor necrosis factor-α medications and pregnancy].
Simon PC; Vallano A
Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
[No Abstract] [Full Text] [Related]
[Next] [New Search]
